<DOC>
	<DOCNO>NCT03070132</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy BIIB074 treat pain experience participant trigeminal neuralgia ( TN ) . Secondary objective study investigate safety tolerability BIIB074 participant TN evaluate population pharmacokinetics ( PK ) BIIB074 .</brief_summary>
	<brief_title>Efficacy Safety Study BIIB074 Participants With Trigeminal Neuralgia</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Trigeminal Neuralgia</mesh_term>
	<criteria>Key A diagnosis trigeminal neuralgia ( TN ) least 3 month base International Headache Society ( IHS ) diagnostic criterion . Participant must fail least 1 prior standard care pharmacologic treatment TN ( define inadequate response intolerance treatment ) , determine Investigator base medical history . Key History positive test result Screening hepatitis C virus antibody current hepatitis B infection ( define positive hepatitis B surface antigen [ HBsAg ] and/or hepatitis B core antibody [ HBcAb ] ) . Positive history human immunodeficiency virus ( HIV ) positive HIV test Screening . Participants facial pain TN . Personal family ( firstdegree relative ) history seizure ( except simple febrile convulsion ) clinically significant head injury . NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>